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Abstract
Introduction: Interleukin-6 (IL-6) is a proinflammatory cytokine that increases early in the serum of patients with
acute kidney injury (AKI). The aim of this study was to determine whether urine IL-6 is an early biomarker of AKI
and determine the source of urine IL-6. Numerous proteins, including cytokines, are filtered by the glomerulus and
then endocytosed and metabolized by the proximal tubule. Since proximal tubule injury is a hallmark of AKI, we
hypothesized that urine IL-6 would increase in AKI due to impaired proximal tubule metabolism of filtered IL-6.
Methods: Urine was collected in 25 consecutive pediatric patients undergoing cardiac bypass surgery (CPB). AKI
was defined as a 50% increase in serum creatinine at 24 hours (RIFLE (Risk, Injury, Failure, Loss, End stage), R).
Mouse models of AKI and freshly isolated proximal tubules were also studied.
Results: Urine IL-6 increased at six hours in patients with AKI versus no AKI (X
2 = 8.1750; P < 0.0042). Urine IL-6 >
75 pg/mg identified AKI with a sensitivity of 88%. To assess whether increased urine IL-6 occurs in functional
versus structural renal failure, mouse models of pre-renal azotemia after furosemide injection (no tubular injury),
ischemic AKI (tubular injury) and cisplatin AKI (tubular injury) were studied. Urine IL-6 did not significantly increase
in pre-renal azotemia but did increase in ischemic and cisplatin AKI. To determine if circulating IL-6 appears in the
urine in AKI, recombinant human (h)IL-6 was injected intravenously and urine collected for one hour; urine hIL-6
increased in ischemic AKI, but not pre-renal azotemia. To determine the effect of AKI on circulating IL-6, serum hIL-
6 was determined one hour post-intravenous injection and was increased in ischemic AKI, but not pre-renal
azotemia. To directly examine IL-6 metabolism, hIL-6 was added to the media of normal and hypoxic isolated
proximal tubules; hIL-6 was reduced in the media of normal versus injured hypoxic proximal tubules.
Conclusions: Urine IL-6 increases early in patients with AKI. Animal studies demonstrate that failure of proximal
tubule metabolism of IL-6 results in increased serum and urine IL-6. Impaired IL-6 metabolism leading to increased
serum IL-6 may contribute to the deleterious systemic effects and increased mortality associated with AKI.
Introduction
IL-6 is a proinflammatory cytokine involved in the acute
phase response to a wide variety of physiologic insults.
For example, serum IL-6 is elevated in patients with
sepsis, acute lung injury (ALI), congestive heart failure,
acute myocardial infarction, and acute kidney injury
(AKI) and predicts increased morbidity and mortality in
these conditions [1-8]. We have recently demonstrated
that serum IL-6 is increased at two hours in patients
with AKI and predicts prolonged mechanical ventilation
in children undergoing cardiac surgery [9]. A pathogenic
role of IL-6 in AKI, ALI, and multiple-organ dysfunction
syndrome has been suggested.
Increased serum IL-6 in patients with critical illness may
be due to multiple factors; for example, increased IL-6
production by stimulated macrophages in injured organs
is well described [10]. In addition to increased production,
it is possible that certain co-existing conditions, such as
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any medium, provided the original work is properly cited.AKI, may reduce serum cytokine clearance. In this regard,
data is accumulating that the kidney plays a key role in
cytokine clearance and metabolism. Because most cyto-
kines are between 10 to 30 kd, filtration of circulating
serum cytokines by the glomerulus is expected. Although
filtration and excretion of the intact cytokine occurs, this
is not the major mechanism of renal cytokine elimination.
Instead, cytokines, like other proteins, are filtered at the
glomerulus and then endocytosed and metabolized by the
proximal tubule [11-16]. Since proximal tubule injury and
dysfunction is the hallmark of AKI, reduced renal IL-6
metabolism might contribute to increased serum IL-6 in
patients with AKI. Paradoxically, impaired proximal tubule
metabolism of IL-6 would also result in increased urine
IL-6; in this case, filtered IL-6 would not be metabolized
by the proximal tubule and would therefore appear intact
in the urine.
In the present study, therefore, we hypothesized that
urine IL-6 would increase in AKI associated with proxi-
mal tubule injury. To test this hypothesis, we measured
urine IL-6 and other cytokines in pediatric patients
undergoing cardiac surgery who did and did not develop
AKI. To examine the role of the kidney and proximal
tubule in cytokine handling, mouse models of ischemic
AKI (renal failure with proximal tubular injury), cispla-
tin-induced AKI (renal failure with proximal tubular
injury), and pre-renal azotemia (renal failure without
proximal tubular injury) were studied. To directly test
the role of proximal tubules in IL-6 metabolism, we uti-
lized freshly isolated proximal tubules exposed to nor-
moxic and hypoxic conditions.
Materials and methods
Patients
After obtaining approval from both the Colorado Insti-
tutional Review Board (COMIRB) and Clinical and
Translational Research Center (CTRC) all children
undergoing scheduled first time cardiopulmonary bypass
(CPB) for repair of congenital heart disease at The Chil-
dren’s Hospital in Denver, Colorado were screened for
inclusion in the study. Patients were excluded if they
had known underlying chronic kidney disease (preopera-
tive estimated Schwartz clearance < 80 ml/min/1.73 m
2),
exposure to nephrotoxins within one week of surgery
(intravenous contrast, aminoglycosides), proteinuria
(dipstick 1+ or greater), urinary tract infection, diabetes,
baseline serum creatinine that was unavailable, or inabil-
ity to obtain consent. Twenty-five patients (aged 8 days
to 14 years; median age 4.4 months) were enrolled
between February 2007 and March 2008. Written
informed consent was obtained for all patients enrolled
in the study prior to any sample collection. Two patients
were subsequently excluded due to gross hemolysis of
the urine samples. Of the 23 patients included in the
analysis, 10 met pre-specified criteria for AKI and 13
did not.
The primary outcome assessed was the development
of AKI post-CPB. AKI was defined, according to RIFLE
criteria R, as a 50% or greater increase in pre-operative
serum creatinine at 24 hours. Other clinical variables
collected and analyzed included duration of cardiopul-
monary bypass (minutes), age, gender, and length of
stay (ICU and hospital). There was no management
component of this study; patients were managed accord-
ing to standard of care.
Patient urine collections
Fresh urine was collected from a Foley catheter at three
time points: pre-operatively and at two and six hours
after coming off CPB. Samples were centrifuged for five
minutes at 2,000 RPM and the supernatant was ali-
quoted and immediately placed in -80°C freezer until
analysis. All samples were analyzed within 15 months of
initial collection.
Urine creatinine and cytokine measurement in patients
Urine creatinine was determined using a quantitative
colorimetric creatinine determination assay (Quanti-
Chrom™ creatinine assay kit-DICT-500) (BioAssay
Systems, Hayward, CA, USA) as described below for
mice. Urine IL-6, IL-8, IL-10, IL-1b,a n dT N F - a were
measured in duplicate using human ELISA kits accord-
ing to assay instructions (R&D Systems, Minneapolis,
MN, USA). The detection limits are as follows: 1) IL-6
is 0.7 pg/mL, 2) TNF-a is 1.6 pg/mL, 3) IL-1b is 1 pg/
mL, 4) IL-8 is 3.5 pg/mL (average of 53 assays), and 5)
IL-10 is 3.9 pg/mL.
Statistical analysis of patient data
Data was analyzed using SAS version 8.1 (SAS Institute,
Inc, Cary, NC, USA) and SPSS 11.5. Given the small
sample size and non-normal distributions, a Wilcoxon
Rank Sum test was used to test for statistically signifi-
cant differences in continuous subject demographics as
well as urine IL-6 at baseline, IL-6 at two hours, and IL-
6 at six hours between subjects with and without AKI.
A chi-square test was used to compare categorical sub-
ject demographic variables. In addition, a receiver oper-
ating characteristic (ROC) curve was used to assess the
relationship between urine IL-6 at six hours and AKI.
Animals
Eight- to ten-week-old male, wild-type, C57BL/6 mice
weighing 20 to 25 g were used (Jackson Labs, Bar
Harbor, ME, USA). Mice were maintained on a standard
diet and water was made freely available. All experi-
ments were conducted with adherence to the NIH
Guide for the Care and Use of Laboratory Animals. The
Dennen et al. Critical Care 2010, 14:R181
http://ccforum.com/content/14/5/R181
Page 2 of 13animal protocol was approved by the Animal Care and
Use Committee of the University of Colorado (Protocol
numbers 81102007(06)1D and 81110(02)1E).
Ischemic AKI and bilateral nephrectomy in mice
Three surgical procedures were performed: (1) sham
operation, (2) ischemic AKI, and (3) bilateral nephrect-
omy, as previously described by our laboratory [17,18].
Briefly, adult male C57B/6 mice were anesthetized with
IP Avertin (2,2,2-tribromoethanol: Aldrich, Milwaukee,
WI, USA), a midline incision was made, the bladder was
emptied of urine by gentle pressure, and the renal pedi-
cles identified. For ischemic AKI, pedicles were clamped
for 22 minutes. After clamp removal, kidneys were
observed for restoration of blood flow by the return to
their original color. Sham surgery consisted of the same
procedure except that clamps were not applied. For
bilateral nephrectomy, both renal pedicles were tied off
with suture, and the kidneys were removed. The abdo-
men was closed in one layer.
Cisplatin model of AKI in mice
Six hours before cisplatin administration, food and water
were withheld. Cisplatin (Aldrich) was freshly prepared
the day of administration in normal saline at a concen-
tration of 1 mg/ml. Mice were given either 30 mg/kg
body weight of cisplatin or an equivalent volume of
vehicle (saline), after which the mice again had free
access to food and water. The cisplatin model of AKI is
well established in our laboratory [19,20].
Pre-renal azotemia (that is, volume depletion) model in
mice
Mice received either 0.5 mg of furosemide (in 100 μL
saline) or vehicle (100 μL saline) intraperitoneally and
food and water were withheld for six hours. At three
hours, vehicle-treated mice received an IP dose of saline
to maintain pre-injection body weight (600 to 1,000 μL)
while furosemide-treated mice received sham injection
(50 μL saline).
Collection and preparation of mouse urine and serum
samples
Immediately post-procedure, mice were placed in urine
collection containers and spontaneously voided urine
was collected. Blood was obtained at sacrifice via cardiac
puncture. To assure uniformity, all samples were pro-
cessed identically. Blood was allowed to clot at room
temperature for two hours then centrifuged at 3,000 g
for 10 minutes. Serum was collected and centrifuged a
second time at 3,000 g for one minute to ensure elimi-
nation of red blood cells. Samples with notable hemoly-
sis were discarded.
Hematocrit
Blood was collected in a capillary tube and spun in a
micro capillary centrifuge (International Equipment
Company, Needham Heights, MA, USA) for three min-
utes. Hematocrit was determined using a micro-hemato-
crit capillary tube reader (Monoject Scientific, St Louis,
MO, USA).
Renal histology
Kidney halves were fixed in 3.78% formaldehyde which
was paraffin embedded, sectioned at 4 μma n ds t a i n e d
with periodic acid-Schiff (PAS) by standard methods.
Creatinine and blood urea nitrogen (BUN) measurement
in mice
Serum and urine creatinine were determined using a
quantitative colorimetric creatinine determination assay
(QuantiChrom™ creatinine assay kit-DICT-500) (BioAs-
say Systems). BUN was measured using a QuantiChrom
assay kit (QuantiChrom™ urea assay kit BIUR-500
(BioAssay Systems)).
Urine, serum, and renal IL-6 measurement
Urine, serum, and renal IL-6 were measured by ELISA
using a species specific (that is, mouse or human) kit
according to assay instructions (R&D Systems). Renal
IL-6 was determined on whole kidney homogenates and
corrected for total protein content using a Bio-Rad DC
protein assay kit (Hercules, CA, USA). The detection
limit of the human IL-6 assay is 0.7 pg/mL; the detec-
tion limit of the mouse IL-6 assay is 1.6 pg/mL.
Injection of recombinant human IL-6
A total of 200 ng of recombinant human IL-6 (hIL-6)
(R&D Systems) or vehicle (PBS with 1% albumin) was
injected via tail vein five hours after 100 μL saline injec-
tion (vehicle), 0.5 mg furosemide injection (pre-renal
azotemia), sham operation, or ischemic AKI. Urine was
collected for one hour after IL-6 injection. At one hour
post-injection, the mice were sacrificed and blood was
obtained.
Addition of recombinant human IL-6 to freshly isolated
mouse proximal tubules
Proximal tubules were isolated from the kidney cortex
using the collagenase digestion and percoll centrifuga-
tion as we have previously described in detail [20]. At
20 minutes of either normoxia or hypoxia, 16.6 ng of
recombinant human IL-6 (hIL-6) was added to media
with and without proximal tubules. At 25 minutes,
samples were centrifuged and washed at 800 g × 2,
and the media and pellet were snap frozen for future
analysis.
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Data were analyzed by one-way analysis of variance at
each time point; if significant F-statistic from analysis of
variance existed, this test was followed by Dunnett post
hoc multiple comparison procedure with sham operation
as the control group. For all other comparisons Stu-
dent’s t-test was used. A P-value of ≤ 0.05 was consid-
ered statistically significant.
Results
Patients
AKI in pediatric patients undergoing cardiopulmonary
bypass is associated with increased ICU and hospital length
of stay
Pre-defined secondary outcome variables included CPB
time and length of stay (ICU and hospital). There was
no difference between the two groups (AKI vs. no AKI)
in duration of CPB. The patients that developed AKI
after CPB had a longer median stay in the ICU (5.5 days
vs. 3 days, P = 0.0166) and longer overall hospital stay
(7.5 days vs. 4 days, P = 0.039). These data are summar-
ized in Table 1. None of the patients with AKI required
renal replacement therapy.
Urine IL-6 is increased at six hours and predicts AKI in
pediatric patients after cardiopulmonary bypass
As shown in Figure 1, the median urine IL-6 (pg/mg
creatinine) was 6 in the no AKI group and 66 in the AKI
group, P = 0.002. No difference was observed between
pre-operative or two hours post-CPB urine IL-6 values in
patients with AKI versus no AKI (P = 0.65).
A ROC curve was calculated for urine IL-6 at six
hours post-CPB. A cut point of 75 pg/mg was selected
to optimize sensitivity and specificity (Figure 2). Eighty-
e i g h tp e r c e n to fs u b j e c t sw i t hA K Ih a da nI L - 6a ts i x
hours greater than 75 whereas only 31% of subjects
without AKI had an IL-6 at six hours greater than 75.
The positive predictive value (PPV) of IL-6 with a cut
point of 75 is 0.6 and the negative predictive value is
0.1. The PPV is the probability that if urine IL-6 is
greater than 75, the patient does indeed have AKI. A
biomarker with higher sensitivity and positive predictive
value will allow for early identification of AKI and facili-
tate evaluation of early intervention trials. Thus, in
terms of diagnostic accuracy, 88% of patients with AKI
had an elevated IL-6 at six hours; in terms of predictive
accuracy, an elevated IL-6 indicates a 60% probability of
being diagnosed with AKI. The C-statistic indicating the
accuracy of IL-6 at six hours to properly classify cases is
0.909.
Urine IL-8, IL-10, IL-1b, and TNF-a are not increased in
patients with AKI
Urine IL-8, IL-10, IL-1b, and TNF-a were determined at
baseline, and two and six hours post-CPB in patients
with and without AKI. No significant difference in any
of these cytokines was noted in patients with AKI versus
no AKI, either corrected (data not shown) or uncor-
rected for urinary creatinine. Urine IL-8 (pg/mL) was
35 ± 17 at baseline; 36 ± 10 in no AKI at two hours,
Table 1 Patient demographics and clinical outcomes for
patients with and without acute kidney injury
No AKI AKI P-value
Median (IQR) Median (IQR)
N1 3 1 0
Age (months) 4.5 (4.18) 4.2 (7.6) 0.9753
Gender (% Male) 54% 50% 0.8548
Duration of CPB (minutes) 98 (80.0) 147.5 (69) 0.1210
ICU length of stay (LOS) 3 (1) 5.5 (6) 0.0166*
Hospital LOS (days) 4 (2) 7.5 (16) 0.0390*
Pre-Operative SCr 0.4 (0.1) 0.35 (0.1) 0.7218
Post-Operative day 1 SCr 0.4 (0.2) 0.6 (0.3) 0.0144*
Post-Operative day 2 SCr 0.3 (0.1) 0.5 (0.4) 0.0351*
Post-Operative day 3 SCr 0.45 (0.3) 0.45 (0.35) 0.7502
AKI, acute kidney injury; CPB, cardiopulmonary bypass; ICU, intensive care
unit; IQR, interquartile range; LOS, length of stay; SCr, serum creatinine. *
Denotes statistical significance, P < 0.05.
Figure 1 Urine IL-6 is increased after cardiopulmonary bypass
in pediatric patients. Urine was collected at baseline and two and
six hours after cardiopulmonary bypass and IL-6 was determined.
Box and whisker plots indicate the 10th, 25th, 50th (median), and
90th percentile values of urinary IL-6. At six hours post-
cardiopulmonary bypass, the median urine IL-6 was significantly
increased in patients with AKI versus those without AKI. No
difference was observed between pre-operative urine IL-6 values in
patients with AKI versus no AKI (P = 0.65). * Denotes statistical
significance, P < 0.002.
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hours, and 37 ± 25 in AKI at six hours (P =N Sf o ra l l
comparisons between groups). Urine IL-10 (pg/mL) was
0±0a tb a s e l i n e ,3±2i nn oA K Ia tt w oh o u r s1 0±8
in AKI at two hours; 1 ± 1 in no AKI at six hours and
0±0i nA K Ia ts i xh o u r s( P = NS for all comparisons
between groups). Urine IL-1b (pg/mL) was 2 ± 1 at
baseline, 3 ± 1 in no AKI at two hours, 4 ± 2 in AKI at
two hours; 3 ± 1 in no AKI at six hours, and 6 ± 2 in
AKI at six hours (P = NS for all comparisons between
groups). Urine TNF-a (pg/mL) was 16 ± 7 at baseline;
10 ± 4 in no AKI at two hours, 8 ± 2 in AKI at two
hours; 18 ± 6 in no AKI at six hours, and 21 ± 8 in AKI
at six hours (P = NS for all comparisons between
groups).
Mice
Mouse models of renal failure
To study the mechanism by which urine IL-6 increases
in patients with AKI, studies were performed in mice.
Characteristics of pre-renal azotemia and ischemic AKI in
mice
To determine if urine IL-6 increased in acute renal fail-
ure associated with structural versus functional changes,
a mouse model of pre-renal azotemia (furosemide injec-
tion) was developed.
Urine volume, percent weight loss, and hematocrit
Urine output was assessed two hours after vehicle or
furosemide injection and was 355 ± 52 μL in vehicle-
treated and 1,419 ± 111 μL in furosemide-treated mice
(P < 0.0001, n = 15 to 16) (Figure 3A). To assess the
magnitude of volume depletion, percent weight loss and
hematocrit were determined six hours after vehicle or
furosemide injection. Percent weight loss was 3 ± 1 in
vehicle-treated mice and 11 ± 1 in furosemide-treated
mice (P < 0.0001, n = 9 to 10) (Figure 3B); hematocrit
(%) was 49 ± 1 in vehicle-treated mice and 58 ± 1 in
furosemide-treated mice (P < 0.0001, n = 9 to 10) (Fig-
ure 3C). Urine output, percent weight loss, and hemato-
crit were similar after sham operation and ischemic AKI
versus vehicle-injection (Figure 3A-C).
BUN and serum creatinine To assess renal function,
BUN and serum creatinine were determined. BUN (mg/
dL) was 15 ± 1 in vehicle-treated, 52 ± 3 in pre-renal azo-
temia (P <0 . 0 0 0 1 ,n = 9 to 10), 24 ± 1 in sham operated,
and 60 ± 1 in ischemic AKI (P < 0.0001 vs. sham; P =N S
vs. pre-renal azotemia, n = 5 to 10) (Figure 3D). Serum
creatinine was 0.4 ± 0.0 in vehicle-treated, 0.5 ± 0.0 in
pre-renal azotemia (P = NS vs. vehicle), 0.5 ± 0.0 in sham
operated, and 1.1 ± 0.1 in ischemic AKI (P <0 . 0 1v s .
sham, pre-renal azotemia, n = 3 to 6) (Figure 3E).
Histology Two hours after ischemic AKI, renal histology
is characterized by patchy necrosis, with several areas of
renal cortex demonstrating normal appearing proximal
tubules with intact brush borders; by six hours post-
ischemic AKI, renal tubular histology is characterized by
Urine IL-6 (pg/mg) Sensitivity 1 - Specificity
0 1.000 1.000
5 1.000 0.923
15 1 000 0 846
75 A B
15 1.000 0.846
25 1.000 0.692
40 1.000 0.615
55 1.000 0.538
65 1.000 0.308
75 0.875 0.308
105 0.750 0.231
150 0.750 0.154
225 0.625 0.154
330 0.625 0.077 330 0.625 0.077
485 0.625 0.000
660 0.500 0.000
875 0.375 0.000
1125 0.250 0.000
6295 0 125 00 0 0 6295 0.125 0.000
11,370 0.000 0.000
Figure 2 Clinical utility of urine IL-6 to diagnose early acute kidney injury. (A) A urine IL-6 of ≥75 pg/mg predicts acute kidney injury with
88% sensitivity. (B) Receiver operating characteristic (ROC) curve for urine IL-6 at six hours after cardiopulmonary bypass.
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border in the majority of proximal tubules. In contrast,
renal histology and the appearance of the proximal
tubules are normal two and six hours after furosemide
injection. Thus, renal structural injury is not a feature in
our model of pre-renal azotemia (Figure 3F-H).
Urine IL-6 increases by six hours in mice with ischemic AKI
To determine if IL-6 appears in the urine in AKI asso-
ciated with proximal tubule injury, urine IL-6 was deter-
mined at two and six hours post-ischemic AKI and two
and six hours in mice with pre-renal azotemia. As
s h o w ni nF i g u r e4 ,u r i n eI L - 6i n c r e a s e ds i g n i f i c a n t l y
after ischemic AKI at six, but not two hours. Urine IL-6
did not increase significantly in mice with pre-renal azo-
temia. These data demonstrate that urine IL-6 increases
with renal failure (increased BUN and creatinine) asso-
ciated with structural proximal tubule injury as judged
by loss of proximal tubule brush border (Figure 3).
Serum IL-6 increases by two hours in mice with ischemic
AKI
We hypothesized that circulating IL-6 filtered by the glo-
merulus would remain in the urine due to a failure of
proximal tubule metabolism. Therefore, we examined
serum IL-6 after ischemic AKI and pre-renal azotemia. As
shown in Figure 4, serum IL-6 was increased at two and
six hours post ischemic AKI. Thus, serum IL-6 increases
prior to the increase in urine IL-6 in ischemic AKI.
Renal production of IL-6 increases by two hours in mice
with ischemic AKI
To examine the source of increased serum IL-6 in mice
with ischemic AKI, renal IL-6 was determined at two, four
and six hours after ischemic AKI. As shown in Figure 4,
renal IL-6 was significantly increased at two, four and six
hours after ischemic AKI versus sham operation. In con-
trast, renal IL-6 did not significantly increase in mice with
pre-renal azotemia, or vehicle injection.
Figure 3 Mouse model of pre-renal azotemia and ischemic AKI. Prerenal azotemia after furosemide injection is characterized by increased
urine output (A), increased total body weight loss (B), increased hematocrit (C), and normal creatinine (D) compared to vehicle injection, sham
operation, and ischemic AKI (urine output was determined at two hours; total body weight loss, hematocrit, and creatinine were determined at
six hours). BUN (E) is increased in both pre-renal azotemia and ischemic AKI (BUN was determined at six hours). Two hours post-ischemic AKI
(F), patchy necrosis with areas of normal proximal tubules in intact brush borders (arrows) is present; at six hours post ischemic AKI (G), proximal
tubule necrosis is wide spread. Renal histology is normal after furosemide injection (H).
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Page 6 of 13Figure 4 Urine, serum, and renal IL-6 in pre-renal azotemia and ischemic AKI. (A) Urine IL-6 increases in mice with ischemic AKI, but not
pre-renal azotemia. Spontaneously voided urine was collected at baseline and from zero to two hours, two to four hours, and four to six hours
after vehicle-injection (Veh), furosemide injection/pre-renal azotemia (Pre), sham operation (Sham) and ischemic AKI (AKI). Urine IL-6 was
increased at four to six hours after ischemic AKI; median and SD (*P < 0.01 vs. Veh, Pre, Sham, n=5 to 7). (B) Serum IL-6 increases in mice with
ischemic AKI prior to the increase in urine IL-6. Serum IL-6 was determined at baseline, and two, four and six hours after vehicle-injection (Veh),
furosemide injection/pre-renal azotemia (Pre), sham operation (Sham) and ischemic AKI (AKI) and was significantly increased at two, four and six
hours after AKI (P < 0.01 vs. Veh, Pre, Sham at all time points; n=4 to 11). (C) Kidney IL-6 increases in mice with ischemic AKI prior to the
increase in urine IL-6. Kidney IL-6 was determined at baseline, and two, four and six hours after vehicle-injection (Veh), furosemide injection/pre-
renal azotemia (Pre), sham operation (Sham) and ischemic AKI (AKI) and was significantly increased at two, four and six hours after AKI (P < 0.01
vs. Veh, Pre, Sham at all time points; n=3 to 7).
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Since we hypothesized that urine IL-6 would increase in
AKI associated with increased serum IL-6 and structural
proximal tubular injury, we examined renal function,
urine IL-6, and serum IL-6 in cisplatin-induced AKI
where the onset of acute tubular necrosis and proximal
tubular injury is well established. Functionally, serum
creatinine and BUN are not increased until day 3 after
cisplatin injection (Figure5 A ,B ) ;h o w e v e r ,p r o x i m a l
tubule injury is apparent on Days 2 and 3 [19,20]. To
determine if urine IL-6 increased at the time of proxi-
mal tubular injury in cisplatin-induced AKI, urine IL-6
was measured on Days 1, 2, and 3 after cisplatin injec-
tion and was significantly increased on Days 2 and 3
(Figure 5C). Thus, increased urine IL-6 coincided with
proximal tubular injury and occurred prior to an ele-
vated serum creatinine. Serum and renal IL-6 were
increased on Days 2 and 3 after cisplatin injection
(Figure 5D,E).
Circulating IL-6 appears in the urine in ischemic AKI in mice
To further test the hypothesis that circulating IL-6 is fil-
tered and appears in the urine during AKI, we examined
the fate of recombinant human IL-6 (hIL-6) injected
intravenously to mice five hours after vehicle injection,
furosemide injection (pre-renal azotemia), sham opera-
tion, ischemic AKI, or bilateral nephrectomy. All urine
was collected for the next one hour after injection and
then the mice were sacrificed and blood collected.
Because human IL-6 does not cross react with murine
IL-6, human IL-6 detected in the blood or urine reflects
the metabolism/elimination of circulating human IL-6
and would not be affected by endogenous IL-6.
As shown in Figure 6A, serum hIL-6 was significantly
increased in mice with ischemic AKI or bilateral
nephrectomy versus vehicle, pre-renal azotemia, and
sham operation. Serum hIL-6 (pg/mL) was 323 ± 68
after vehicle injection, 394 ± 40 in pre-renal azotemia
(P = NS versus vehicle injection, n = 3 to 4), 265 ± 57
after sham operation, 4,609 ± 1,052 after ischemic AKI
(P < 0.001 vs. sham, n=3 to 4), and 16,115 ± 862 after
bilateral nephrectomy (P < 0.0001 vs. sham, n=3t o4 ) .
These data demonstrate that hIL-6 elimination from the
serum is intact in mice with functional kidneys (vehicle
injection, pre-renal azotemia, and sham operation) but
is greatly reduced in mice with impaired (ischemic AKI)
or absent kidney function (bilateral nephrectomy).
Although both levels were markedly increased, the level
of serum hIL-6 was higher in mice after bilateral
n e p h r e c t o m yv e r s u si s c h e m i cA K I .W eh a v ep r e v i o u s l y
demonstrated that the glomerular filtration rate (GFR)
in our model of ischemic AKI is approximately 10% of
normal [21] or 25 μL/minute [22]. Since the mice with
bilateral nephrectomy have a GFR of zero, these data
suggest that the residual kidney function in mice with
ischemic AKI may have contributed to IL-6 elimination/
metabolism.
As shown in Figure 6B, urine hIL-6 was significantly
increased in mice with ischemic AKI versus vehicle injec-
tion, pre-renal azotemia, and sham operation. Urine hIL-
6 (pg/mL) was 1 ± 1 in vehicle-injected mice, 9 ± 6 in
pre-renal azotemia, 14 ± 14 in sham operated mice, and
2,411 ± 777 in mice with ischemic AKI (P <0 . 0 5 ;n =3
to 4). Similar significance was obtained when urine rhIL-
6 was corrected for urine creatinine. These results
demonstrate that significantly more filtered hIL-6
appears in the urine in mice with impaired kidney func-
tion (ischemic AKI) than in mice with intact kidney func-
tion (vehicle injection, pre-renal azotemia, and sham
operation). (Mice with bilateral nephrectomy are anuric,
therefore, no urine values are reported for this group).
To confirm that murine IL-6 is not detected by the
human IL-6 ELISA, recombinant murine IL-6 at 1,000,
500, 100, and 65 pg/mL concentrations were assayed
with the human ELISA kit and no human IL-6 was
detected. Thus, hIL-6 detected in the serum and urine
post-injection of hIL-6 is not indicative of endogenous
(murine) production of IL-6, but does reflect the meta-
bolism/elimination of circulating IL-6 in AKI.
Addition of recombinant human IL-6 to murine proximal
tubules
To directly examine the role of renal proximal tubules
in IL-6 metabolism, freshly isolated proximal tubules or
media containing 1% BSA were exposed to 20 minutes
of normoxia or hypoxia at which time 16.6 ng of recom-
binant human IL-6 (hIL-6) was added to the media.
After five minutes, percent LDH release and media hIL-
6 was determined.
The percent of LDH release is a measure of hypoxia-
induced membrane injury and increased percent LDH
release is an indicator of proximal tubular necrosis (that
is, the higher the percent LDH, the higher the degree of
proximal tubular membrane disruption). The percent of
LDH release was 7 ± 1 in normoxic proximal tubules +
h I L - 6a n dw a s3 6±2i nh y p o x i cp r o x i m a lt u b u l e s( P <
0.0001, n=5 to 6). In separate experiments, percent
LDH was determined in normoxic and hypoxic proximal
tubules without addition of hIL-6 to ensure that the
addition of hIL-6 did not have an effect on membrane
injury; in these experiments percent LDH release was
11 ± 1 in normoxic proximal tubules (P =N Sv s .n o r -
moxic proximal tubules + hIL-6, n=5t o6 )a n dw a s
34 ± 4 in hypoxic proximal tubules (P = NS vs. hypoxic
proximal tubules + hIL-6). Thus, addition of hIL-6 did
not affect hypoxia-induced membrane injury.
As shown in Figure 7, IL-6 (pg/mL) was 1,018 ± 98 in
the normoxic media without proximal tubules and was
1,105 ± 62 in the hypoxic media without proximal
tubules (P = NS). In the normoxic media with proximal
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nomoxic media without proximal tubules and hypoxic
media without proximal tubules). In the hypoxic media
with proximal tubules, IL-6 was 869 ± 44 (P < 0.05 ver-
sus normoxic media with proximal tubules.
To determine if hIL-6 is resorbed by renal proximal
tubules and remains intact, hIL-6 was measured in the
proximal tubule pellets after centrifugation. hIL-6 (pg)
was 18 ± 3 in normoxic proximal tubules and was 8 ± 1
in hypoxic proximal tubules (P < 0.01, n=5 to 6). Since
very little intact hIL-6 was contained in renal proximal
tubules, these data demonstrate that hIL-6 is degraded
in the presence of renal proximal tubules and that
h y p o x i cp r o x i m a lt u b u l e sa r el e s sa b l et om e t a b o l i z e
hIL-6 than normoxic proximal tubules.
Discussion
Herein, we demonstrate that urine IL-6 increased by six
hours in pediatric patients with AKI after cardiopulmon-
ary bypass (CPB) and is thus a potential early biomarker
of AKI. The development of biomarkers that can iden-
tify AKI early is a translational research priority [23] as
Figure 5 Renal function and urine, serum, and renal IL-6 in cisplatin-induced AKI. (A) Serum creatinine and (B) BUN increase on Day 3 in
mice with cisplatin-induced AKI. Serum creatinine and BUN were determined on Days 1, 2 and 3 after vehicle or cisplatin injection and was
significantly increased on Day 3 (P < 0.05 for creatinine and P = 0.0001 for BUN vs. Veh; n=5 to 12). (C) Urine IL-6 increases on Days 2 and 3 in
mice with cisplatin-induced AKI. Urine was collected at the time of sacrifice on Days 1, 2 and 3 after vehicle or cisplatin injection. Urine IL-6 did
not increase significantly until Days 2 and 3 after cisplatin injection, when proximal tubule injury is present (P < 0.002 vs. Veh, n=5 to 12). (D)
Serum IL-6 increases on Days 2 and 3 in mice with cisplatin-induced AKI. Serum IL-6 was determined on Days 1, 2 and 3 after vehicle or cisplatin
injection and was significantly increased on Days 2 and 3 (P < 0.05 on Day 2 and P < 0.0001 on Day 3 vs. Veh; n=5 to 12). (E) Kidney IL-6
increases on Day 3 in mice with cisplatin-induced AKI. Kidney IL-6 was determined on Days 1, 2 and 3 after vehicle or cisplatin injection and was
significantly increased on Day 3 (P < 0.01 on Day 3 vs. Veh; n=5 to 12).
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be due the dependence on serum creatinine, a late mar-
ker of kidney injury [24], to diagnose AKI. Multiple
serum and urine biomarkers are currently being tested
for their ability to diagnose AKI. It is unlikely, however,
that one biomarker will be able to accurately diagnose
AKI;panels of biomarkers will be required [25]. Thus,
the identification of new biomarkers that can enhance
the diagnostic potential of currently studied biomarkers
is still needed.
To examine the diagnostic utility of increased urine
IL-6 in patients with AKI, we studied animal models of
ischemic AKI, cisplatin-induced AKI, and pre-renal azo-
temia. We found that urine, serum, and renal IL-6 were
all increased in mice with ischemic AKI and cisplatin-
induced AKI, but not pre-renal azotemia. Ischemic AKI
and cisplatin-induced AKI are both associated with
proximal tubule injury and acute tubular necrosis
(ATN), while proximal tubule injury and necrosis are
absent in our model of pre-renal azotemia. ATN from
ischemia and nephrotoxins are the most common causes
of AKI in hospitalized patients and distinguishing pre-
renal azotemia from ATN remains a challenging clinical
dilemma [26], thus, increased urine IL-6 may have clini-
cal utility for this purpose. It is important to note, how-
ever, that urine IL-6 was not zero with pre-renal
azotemia and certain controls; therefore, small amounts
of IL-6 may appear in the urine in the absence of struc-
tural renal injury. Thus, as with most biomarkers, it will
be important to establish what level of urine IL-6 is
clinically significant in regard to the identification of
ATN or AKI. The increase in renal and serum IL-6 con-
firm previous studies [10,17,18] and highlight the early
Figure 6 Fate of intravenously injected recombinant human IL-6 in pre-renal azotemia, ischemic AKI, and bilateral nephrectomy.A
total of 200 ng of recombinant human (h) IL-6 was administered by tail vein injection five hours after vehicle-injection (Veh), furosemide
injection/pre-renal azotemia (Pre), sham operation (Sham), ischemic AKI (AKI), or after bilateral nephrectomy. Urine was collected for one hour
and serum was collected at one hour. (A) Serum human IL-6 is elevated in mice with ischemic AKI and bilateral nephrectomy versus vehicle
injection, pre-renal azotemia, and sham operation (*P < 0.01 versus vehicle injection, pre-renal azotemia, and sham operation, n=4; **P < 0.05
versus ischemic AKI). (B) Urine human IL-6 is increased in mice with ischemic AKI versus vehicle injection, pre-renal azotemia, and sham
operation (***P < 0.01 versus vehicle injection, pre-renal azotemia, and sham operation, n=4 to 5). (Mice with bilateral nephrectomy are anuric;
therefore, no urine values are reported for this group).
Figure 7 Addition of recombinant human IL-6 to freshly
isolated proximal tubules. A total of 200 ng of recombinant
human (h) IL-6 was added to media with and without freshly
isolated proximal tubules after 20 minutes of either normoxic or
hypoxic conditions. Media human IL-6 concentration was
determined after five minutes of incubation. Human IL-6 was
significantly reduced in the media containing normoxic proximal
tubules versus normoxic and hypoxic media without proximal
tubules (*P < 0.02, n=5 to 6). Media human IL-6 was higher in
hypoxic proximal tubules versus normoxic proximal tubules (†P =
0.05, n=6).
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increased serum IL-6 relative to increased urine IL-6 is
consistent with our hypothesis that serum/circulating
IL-6 appears in the urine in AKI with proximal tubular
injury.
To test our hypothesis that serum/circulating IL-6 is
filtered and remains intact in the urine in AKI with prox-
imal tubule injury, hIL-6 was given intravenously to mice
with pre-renal azotemia (renal failure without proximal
tubule injury) or ischemic AKI (renal failure with proxi-
mal tubule injury) and urine was collected for one hour.
The use of hIL-6 in this experiment is advantageous
because it is homologous to murine IL-6 and expected to
be handled in a similar manner, but it does not cross
react with murine IL-6 on the ELISA test used to mea-
sure it; thus, potential confounding effects of endogenous
murine IL-6 production are avoided. If our hypothesis
that circulating IL-6 is filtered by the glomerulus and
then resorbed and metabolized by the proximal tubule
were correct, then urine hIL-6 would be low in mice with
functioning kidneys and high in mice with AKI. Indeed,
urine hIL-6 was dramatically increased in ischemic AKI
and was reduced in pre-renal azotemia and controls with
normal renal function. Finally, to directly examine IL-6
metabolism by proximal tubules, hIL-6 was added to the
media of normal and hypoxic isolated proximal tubules
and hIL-6 was reduced in the media of normal versus
injured hypoxic proximal tubules. Together these data
suggest that renal filtration coupled with impaired proxi-
mal tubule metabolism of IL-6 contributes to the
increase in urine IL-6 observed in AKI.
Although previous studies have not examined the effect
of AKI on renal IL-6 handling, our data demonstrating a
role of the kidney in the filtration and metabolism of IL-6
are consistent with the known role of the proximal tubule
in protein metabolism. Other proteins that are filtered at
the glomerulus and then endocytosed and metabolized
by the proximal tubule include light chains [27], hor-
mones (for example, insulin, parathyroid hormone),
small peptides, and b2-microglobulin [28]. The role of
the kidney in the clearance and metabolism of IL-6 [29]
and other cytokines such as IL-1, GCSF, and IL-10 has
also been described [11-16]. In fact, data suggest that
renal proximal tubule metabolism is responsible for at
least 10% of cytokine elimination [16,29].
How does impaired renal elimination/metabolism of
IL-6 affect serum levels? We found that serum levels of
hIL-6 were markedly elevated in mice with ischemic
AKI or bilateral nephrectomy one hour after IV injec-
tion, but were reduced in mice with normal renal func-
tion or pre-renal azotemia. Thus, AKI was associated
with sustained levels of serum IL-6. The clinical rele-
vance of these findings is notable since proinflammatory
cytokines such as IL-6 are known to mediate organ
dysfunction. Since numerous insults causing IL-6 pro-
duction may occur in patients with AKI (for example,
hemorrhage, infection), impaired metabolism with sys-
temic accumulation of IL-6 may contribute to the
adverse clinical outcomes associated with AKI, particu-
larly in the setting of the systemic inflammatory
response syndrome and multiple organ dysfunction
syndrome.
Our pilot study in patients, although promising, has a
few important limitations. First, although elevated serum
IL-6 after CPB is well described, serum IL-6 was not mea-
sured in our patients. Because a key source of urine IL-6 is
circulating serum IL-6, the potential role of urine IL-6 as a
biomarker of AKI may depend on the availability of tan-
dem serum and urine IL-6 values. Second, results were
obtained in a small number of homogenous pediatric
patients from a single center. Third, the cause of AKI was
not specifically assessed, although it is presumed to be due
to ATN. Finally, although other urine cytokines (for exam-
ple, IL-8, IL-10, IL-1b, TNF-a) were not predictive of AKI
in this population, it is possible that these cytokines may
have diagnostic utility in other forms of AKI. For example,
urine IL-6 [30], IL-8 [30], and Gro-a [31] were increased
post-transplant in patients with delayed graft function.
Ours is the first study to examine the utility of these urine
cytokines to diagnose AKI in patients with native kidneys;
thus, further studies will need to be performed to deter-
mine whether urine IL-6 or other urine cytokines are
useful to diagnose AKI in conditions other than post-
cardiopulmonary bypass.
Conclusions
The identification of early biomarkers of AKI is critical
for the development of successful treatments to improve
kidney function and reduce systemic complications. We
demonstrate that increased urine IL-6, using a cut point
of 75 pg/mg, can diagnose AKI post-cardiopulmonary
bypass with 88% sensitivity within six hours of CPB. In
animal models, we demonstrate that 1) renal IL-6 pro-
duction and serum IL-6 increase early in AKI, 2) urine
IL-6 increases in AKI associated with ATN, 3) renal
elimination of IL-6 is impaired in AKI. Thus, AKI may
be a unique clinical scenario where increased production
and impaired elimination of cytokines occurs; the resul-
tant increase in systemic cytokine burden may contri-
bute to the increased morbidity and mortality of
patients with AKI. Since IL-6 is known to be a mediator
of both AKI and ALI, IL-6 may be both a diagnostic
marker of AKI as well as a therapeutic target.
Key messages
￿ The proinflammatory cytokine IL-6 increases early
(at six hours) in patients with acute kidney injury
due to cardiopulmonary bypass.
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Page 11 of 13￿ Animal studies demonstrate that urine IL-6
increases significantly in acute kidney injury due to
acute tubular necrosis (ischemia and cisplatin), but
not pre-renal azotemia.
￿ Animal studies demonstrate that failure of renal
IL-6 metabolism results in an increase in both
serum and urine IL-6.
￿ Urine IL-6 may be a useful early biomarker to detect
acute kidney injury from acute tubular necrosis.
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